Compare Becton Dickinson and Co (BDX) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Nvidia Corp — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Nvidia Corp trades at $211.55 (market cap $5.13T). The key difference: Nvidia Corp is far larger — about 123.6× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | NVDA | |
|---|---|---|
Market Cap | $41.51B | $5.13T |
Sector | Health | Technology |
52-Week High | $185.39 | $235.75 |
52-Week Low | $135.49 | $165.17 |
Enterprise Value | $57.97B | $5.06T |
Dividend Yield | 2.79% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
NVIDIA (NVDA) trades at $203.53, down 3.52% on the day, with a bullish technical outlook supported by moving averages and key support at $201. The company reported strong revenue growth to $130.50B in 2025, with net income surging to $72.88B and a robust net margin of 55.84%. Recent earnings beats and a consensus analyst price target of $325.86 highlight strong fundamental momentum amid AI-driven demand.
Outlook remains positive with AI infrastructure expansion driving growth, though risks include increased competition and market volatility. Wall Street sentiment is bullish with 75% buy ratings, but investors should monitor execution risks and macroeconomic headwinds that could impact valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
